Planning Capital Management Corporation’s Summit Therapeutics SMMT Stock Holding History

Planning Capital Management Corporation’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$22	Buy	+1	New	+$14	﹤0.01%	765

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Planning Capital Management Corporation's SMMT Position: Q3 2024 in Review

Planning Capital Management Corporation opened a new position in Summit Therapeutics (SMMT) in Q3 2024: 1 share worth $22. The stake represents ﹤0.01% of the portfolio and ranks #765 among its holdings.

166 funds tracked by Wall St. Rank hold SMMT as of Q3 2024.

Planning Capital Management Corporation held 1 share of Summit Therapeutics worth $22 as of Q3 2024.
Summit Therapeutics was a new Planning Capital Management Corporation position in Q3 2024.
Summit Therapeutics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #765 holding.
166 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.